Teva posts strong revenue growth as branded drugs surpass $1 billion, despite acquisition-driven loss...

Teva reported revenue that exceeded expectations, driven by branded drugs surpassing $1 billion in sales. The company also raised its outlook based on the stronger performance.

The Emalex acquisition produced a quarterly net loss despite the revenue gains.